GeneThera, Inc. (GTHR)

USD 0.0

(0.0%)

Market Cap (In USD)

3533.00

Revenue (In USD)

-

Net Income (In USD)

-

Avg. Volume

80.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-6-0.006
PE
-
EPS
-
Beta Value
0.14
ISIN
US37185E3062
CUSIP
37185E306
CIK
1017110
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Antonio Milici M.D., Ph.D.
Employee Count
-
Website
https://www.genethera.net
Ipo Date
2012-09-25
Details
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company's Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. GeneThera, Inc. is based in Westminster, Colorado.